Narita, Yukiya
Ogata, Takatsugu
Ishizuka, Yasunobu
Sakakida, Tomoki
Wakabayashi, Munehiro
Kodama, Hiroyuki
Honda, Kazunori
Masuishi, Toshiki
Taniguchi, Hiroya
Kadowaki, Shigenori
Ando, Masashi
Tajika, Masahiro
Muro, Kei
Article History
Received: 5 January 2024
Accepted: 13 May 2024
First Online: 3 June 2024
Competing interests
: The authors declare the following financial interests/personal relationships which may be considered potential competing interests: Y Narita: research funding to my institution from Chugai, MSD, Amgen, ONO Pharmaceutical, Astellas, Sanofi, Taiho, Eisai, Daiichi Sankyo, Novartis, and Pfizer; honoraria for lectures, presentations, and speaker bureaus from Yakult Honsha, Taiho, Eli Lilly, Daiichi Sankyo, Ono Pharma, and Bristol-Meyers Squibb and; participation on the Advisory Board of Daiichi Sankyo. T Ogata: personal fees from ONO Pharmaceutical, personal fees from BMS, personal fees from Taiho, personal fees from Daichi-Sankyo, outside the submitted work. H Kodama: honoraria for lectures, presentations, and speaker bureaus from Taiho. K Honda: grants from Pfizer, outside the submitted work; T Masuishi: grants and personal fees from MSD, grants and personal fees from Amgen, grants and personal fees from ONO Pharmaceutical, grants and personal fees from Daiichi Sankyo, grants from Novartis, grants from Pfizer, personal fees from Taiho, personal fees from Bristol Myers Squibb, personal fees from Eli Lilly, personal fees from Takeda, grants from Boehringer-Ingelheim, grants from Syneos Healthe Clinical, personal fees from Chugai, personal fees from Nippon Kayaku, grants from Cimic Shift Zero, personal fees from Merck Bio Pharma, personal fees from Bayer, personal fees from Yakult Honsha, personal fees from Sanofi, personal fees from ONO Pharmaceutical, outside the submitted work. H Taniguchi: grants and personal fees from Takeda, grants from Daiichi Sankyo, grants and personal fees from ONO Pharmaceutical, personal fees from Eli Lilly, personal fees from Merck Biopharma, personal fees from Chugai, outside the submitted work; Dr. Kadowaki reports grants and personal fees from Eli Lilly, grants from Nobelpharma, grants and personal fees from Taiho, grants and personal fees from MSD, grants and personal fees from Bayer, grants from Yansen, grants and personal fees from Chugai, grants and personal fees from ONO Pharmaceutical, grants from Daiichi Sankyo, personal fees from Merck, personal fees from BMS, outside the submitted work; S Kadowaki: Grants or contracts from Eli Lilly, Ono, Bayer,Daiichi Sankyo, MSD, Chugai, Janssen, Nobelpharma, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Bristol-Myers Squibb, Ono, Bayer, Merck Biopharma, Taiho, Eisai, Daiichi Sankyo, MSD, Chugai, Otsuka Pharmaceutical. M Ando: personal fees from Eisai Co., Ltd., personal fees from ONO Pharmaceutical, personal fees from Chugai Pharmaceutical Co. Ltd, personal fees from Mundipharma Co., Ltd., personal fees from Taiho Pharmaceutical Co., Ltd., outside the submitted work. M Tajika: personal fees from Bristol Myers Squibb, outside the submitted work. K Muro: research funding to my institution from Chugai, MSD, Amgen, ONO Pharmaceutical, Astellas, Sanofi, Taiho, Eisai, Daiichi Sankyo, Novartis, and Pfizer; consulting fees from AstraZeneca, ONO Pharmaceutical, Amgen, and Astellas; honoraria for lectures from ONO Pharmaceutical, Taiho, Bristol-Myers Squibb, Eli Lilly, MSD, and Daiichi Sankyo; participation on the advisory boards of ONO Pharmaceutical, Amgen, AstraZeneca, Eli Lilly, and Takeda.